5-Fluorouracil (5FU)

DRUG3 trials

Sponsors

Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca

Conditions

Breast CancerCancerSquamous Cell Carcinoma of the Head and Neck

Phase 1

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

CompletedNCT01653470

Bristol-Myers SquibbCancer

Start: 2012-10-12End: 2017-05-08Updated: 2020-01-28

Phase 2

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

CompletedNCT00773695

Hoffmann-La RocheBreast Cancer

Start: 2008-11-07End: 2022-11-09Updated: 2023-01-09

Phase 3

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

CompletedNCT02551159

AstraZenecaSquamous Cell Carcinoma of the Head and Neck

Start: 2015-10-15End: 2021-05-21Updated: 2021-10-13

Related Papers

Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance.

2026-01-02

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy

Breast Cancer Research2025-08-111 citations

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.

2024-03-025 citations

Abstract 5627: Spatial protein profiling by cyclic immunofluorescence to interpret and improve bulk tumor-based predictor of response to chemotherapy with bevacizumab in neoadjuvant breast cancer treatment

Cancer Research2023-04-04

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Journal of Clinical Oncology2022-12-06140 citations

591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data

Regular and Young Investigator Award Abstracts2022-11-01

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

2019-01-1436 citations

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.

2018-11-2920 citations

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

Journal of Clinical Oncology2016-05-2032 citations

Molecular characteristics in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva— Randomized phase II study.

Journal of Clinical Oncology2015-05-201 citations